Rhumbline Advisers reduced its position in shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) by 70.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,514 shares of the company's stock after selling 27,428 shares during the quarter. Rhumbline Advisers' holdings in Zenas BioPharma were worth $91,000 as of its most recent SEC filing.
Zenas BioPharma Price Performance
Shares of NASDAQ ZBIO traded up $0.11 during midday trading on Monday, reaching $9.69. The stock had a trading volume of 165,539 shares, compared to its average volume of 217,038. The company has a market cap of $405.33 million and a P/E ratio of -2.73. Zenas BioPharma, Inc. has a 12-month low of $5.83 and a 12-month high of $26.25. The business's 50-day simple moving average is $10.24.
Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its earnings results on Thursday, May 15th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.15) by $0.35. The firm had revenue of $10.00 million during the quarter, compared to the consensus estimate of $5.00 million.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on ZBIO shares. HC Wainwright restated a "buy" rating and issued a $30.00 price objective on shares of Zenas BioPharma in a research note on Friday, May 16th. Guggenheim restated a "buy" rating and issued a $45.00 price target on shares of Zenas BioPharma in a research report on Wednesday, March 12th. Finally, Wedbush reaffirmed an "outperform" rating and set a $35.00 price objective on shares of Zenas BioPharma in a research report on Thursday, May 15th.
Read Our Latest Research Report on ZBIO
About Zenas BioPharma
(
Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Recommended Stories
Before you consider Zenas BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas BioPharma wasn't on the list.
While Zenas BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
